Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
about
Combination treatment including targeted therapy for advanced hepatocellular carcinomaHigher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
P2860
Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Bevacizumab enhances chemosens ...... bition of survivin expression.
@en
Bevacizumab enhances chemosens ...... bition of survivin expression.
@nl
type
label
Bevacizumab enhances chemosens ...... bition of survivin expression.
@en
Bevacizumab enhances chemosens ...... bition of survivin expression.
@nl
prefLabel
Bevacizumab enhances chemosens ...... bition of survivin expression.
@en
Bevacizumab enhances chemosens ...... bition of survivin expression.
@nl
P2093
P2860
P1476
Bevacizumab enhances chemosens ...... bition of survivin expression.
@en
P2093
Hua-Xiang Xu
Hui-Chuan Sun
Ju-Bo Zhang
Ling-Qun Kong
Lun-Xiu Qin
Peng-Yuan Zhuang
Wei-Zhong Wu
Xiao-Dong Zhu
Yu-Quan Xiong
P2860
P2888
P304
P356
10.1007/S00432-010-0914-8
P577
2010-05-21T00:00:00Z